Frontiers Case report: Short-term eculizumab use in atypical HUS

Por um escritor misterioso

Descrição

Frontiers  Case report: Short-term eculizumab use in atypical HUS
COVID-19 Triggers Relapse in Woman With aHUS: Case Study
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Frontiers  Case report: Short-term eculizumab use in atypical HUS
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Frontiers  Case report: Short-term eculizumab use in atypical HUS
Frontiers Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF] Atypical hemolytic uremic syndrome: a syndrome in need of clarity
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF] Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab
Frontiers  Case report: Short-term eculizumab use in atypical HUS
Optimal management of atypical hemolytic uremic disease: challenges an
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses
Frontiers  Case report: Short-term eculizumab use in atypical HUS
PDF] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
de por adulto (o preço varia de acordo com o tamanho do grupo)